Esperion Therapeutics, Inc. - Common Stock — 분기별 재무 통계 (NASDAQ:ESPR)

Financials

영업활동으로 인한 현금 -34.95 M-22.63 M-31.42 M-4.29 M45.24 M-27.72 M -18.19 M 투자 활동으로 인한 현금 00000-189 K -189 K 재무활동으로 인한 현금 35 M-7.5 M2.85 M10.67 M30.16 M16.22 M 59.9 M 잉여 현금 흐름 -34.95 M-22.63 M-31.42 M-4.29 M45.24 M-27.72 M -18.19 M

Esperion Therapeutics, Inc. - Common Stock

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

ESPR

Financials

Esperion Therapeutics, Inc. - Common Stock

뉴스

Epilogue On Esperion Therapeutics Stock (NASDAQ:ESPR)

ESPR Stock Surges 44% in a Month: Here's What You Need to Know

Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?

Karyopharm Therapeutics (KPTI) Stock Jumps 6.9%: Will It Continue to Soar?

에스페리온 테라퓨틱스, BofA ’저조’ 투자의견 유지

BofA reiterates Esperion Therapeutics stock Underperform rating

벰페도산, 콜레스테롤 치료제 최고 등급 권고 획득

Bempedoic acid gains top-level guideline recommendations for cholesterol

시티즌스, 에스페리온 테라퓨틱스 목표가 상향 조정

Citizens raises Esperion Therapeutics price target on drug growth

ESPR's Q4 Earnings Lag Estimates, Revenues Beat, Stock Down

H.C. 웨인라이트, 에스페리온 주식에 ’매수’ 의견 유지, 목표가 16달러